Radionuclide therapy

Lancet

Volumn 354, Issue 9182, 1999, Pages 931-935

  Chatal, Jean Francois ^a   Hoefnagel, Cornelis A ^b  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ASTATINE 211; BISMUTH; COMPLEMENTARY DNA; COPPER; INDIUM 111; IODINE 131; IODOBENZOIC ACID DERIVATIVE; PEPTIDE; PHOSPHORUS 32; RADIOISOTOPE; RHENIUM 186; SAMARIUM 153; SOMATOSTATIN; STRONTIUM 89; TIN; YTTRIUM 90; YTTRIUM SILICATE Y 90;

ARTHRITIS; BEAM THERAPY; BONE MARROW DISEASE; BONE METASTASIS; BRACHYTHERAPY; CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; COLLOID; COMPARATIVE STUDY; DISEASE CONTROL; HALF LIFE TIME; HEMATOLOGIC DISEASE; HUMAN; INFERTILITY; INTRAARTICULAR DRUG ADMINISTRATION; LEUKEMIA; METASTASIS; NUCLEAR MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; RADIOIMMUNOTHERAPY; RHEUMATOID ARTHRITIS; RISK FACTOR; SHORT SURVEY; TARGET ORGAN; THYROID CARCINOMA; THYROTOXICOSIS; TUMOR;

EID: 0033546884     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)06002-X     Document Type: Review

References (21)

1. 90Y. Radiother Oncol. 21:1991;91-99.
2. Humm J.L., Cobb L.M. Nonuniformity of tumour dose in radioimmunotherapy. J Nucl Med. 31:1990;75-83.
3. Hoefnagel C.A., Clarke S.E.M., Fischer M.et al. Radionuclide therapy practice and facilities in Europe. Eur J Nucl Med. 26:1999;277-282.
4. Schlumberger M., Challeton C., De Vathaire F.et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med. 37:1996;598-605.
5. Schlumberger M., Arcangioli O., Piekarski J.D.et al. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med. 29:1988;1790-1794.
6. 131I] metaiodobenzylguanidine in the treatment of neural crest tumours. J Nucl Biol Med. 35:1991;177-362.
7. De Kraker J., Hoefnagel C.A., Caron H.et al. First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma. Eur J Cancer. 31A:1995;600-602.
8. Taal B.G., Hoefnagel C.A., Valdés Olmos R.A.et al. The palliative effect of metaiodobenzylguanidine (MIBG) in metastatic carcinoid tumours. J Clin Oncol. 14:1996;1829-1838.
9. Robinson R.G., Preston D.F., Schiefelbein M.et al. Strontium-89 therapy for the palliation of pain due to osseous metastases. JAMA. 274:1995;420-424.
10. Quirijnen J.M.S.P., Han S.H., Zonnenberg M.et al. Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain. J Nucl Med. 37:1996;1511-1515.
11. Serafini A.N., Houston S.J., Resche I.et al. Palliation of pain associated with metastatic bone cancer using samarium-153 Lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 16:1998;1574-1581.
12. Raoul J-L., Guyader D., Bretagne J-F.et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med. 35:1994;1782-1787.
13. Maloney D.G., Grillo-Lopez A.J., White C.A.et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 90:1997;2188-2195.
14. Wahl R.L., Zasadny K.R., NacFarlane D.et al. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan phase I experience. J Nucl Med. 39:1998;21-27.
15. Lui S.Y., Eary J.F., Petersdorf S.H.et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labelled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol. 16:1998;3270-3278.
16. Chatal J.F., Mahé M. Therapeutic use of radiolabelled antibodies. In: Murray I.P.C., Ell P.J., ed. Nuclear medicine in clinical diagnosis and treatment, 2nd ed. Edinburgh: Churchill Livingstone, 1998; 1101-14.
17. Reubi J.C. Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q J Nucl Med. 41:1997;63-70.
18. Stolz B., Weckbecker G., Smith-Jones P.M.et al. The somatostatin receptor-targeted radiotherapeutic [Y-90-DOTA-Dphe(1), Tyr(3)] octreotide (Y-90-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med. 25:1998;668-674.
19. Otte A., Müller-Brand J., Dellas S.et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 351:1998;417-418.
20. Hnatowich D.J. Antisense and nuclear medicine. J Nucl Med. 40:1999;693-703.
21. McDevitt M.R., Sgouros G., Finn R.D.et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med. 25:1998;1341-1351.